ACADIA Pharmaceuticals Announces Appointment of Terrence Moore as Executive Vice President and Chief Commercial Officer

SAN DIEGO—(BUSINESS WIRE)—Aug. 19, 2013—ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical companyfocused on innovative treatments that address unmet medical needs inneurological and related central nervous system disorders, announced theappointment of Terrence Moore as Executive Vice President and ChiefCommercial Officer, effective today. Mr. Moore reports to ACADIA’s ChiefExecutive Officer, Uli Hacksell, Ph.D., and will be responsible forleading ACADIA’s commercial activities.

“Terry is an exceptional individual who brings a wealth of commercialexperience to ACADIA from a variety of senior roles at several leadingpharmaceutical companies. He has made key contributions to the buildingof multi-billion dollar brands in the CNS field, including Prozac^®,Zyprexa^®, Risperdal^®, and Effexor XR^®,”said Dr. Hacksell. “Terry’s marketing expertise and demonstrated abilityto execute will help position ACADIA for success in the planned launchof pimavanserin in Parkinson’s disease psychosis and for effective lifecycle management in order to maximize pimavanserin’s commercialpotential.”

Mr. Moore has more than 25 years of experience as a senior member ofsales and marketing teams at several pharmaceutical companies. Mostrecently, Mr. Moore was a principal of Cook-Moore Consulting and, beforefounding the firm, served as Vice President at TransceptPharmaceuticals, where he was responsible for commercial strategy,business development and commercial alliance activities. Previously, Mr.Moore served as Vice President, U.S. Head of Neuroscience Marketing atOrganon BioSciences and was responsible for the creation and building ofits Neuroscience Business Unit. He also served as Vice President, U.S.Marketing, Effexor XR^®, as well as Vice President, GlobalStrategy Depression Portfolio at Wyeth Pharmaceuticals. Earlier, Mr.Moore held senior management positions at Johnson & Johnson, where hehelped to launch Risperdal^® for additional indications in theU.S., and at Eli Lilly, where he held various sales and marketing rolesover 11 years, including Zyprexa^® Brand Manager.

Mr. Moore holds a B.S. degree in Pharmacy from the University ofFlorida, a B.A. degree in Chemistry from the University of South Floridaand has completed executive development programs at the Kellogg Schoolof Management and Wharton School of Business.

“I am very pleased to be joining an organization dedicated to meetingthe needs of patients suffering from neurological disorders and thosewho are responsible for providing their care,” said Mr. Moore. “It is anexciting time at ACADIA as the company advances toward an NDA submissionfor pimavanserin and accelerates its pre-commercial activities. I lookforward to working with the ACADIA team to achieve the goal of bringingthis innovative product to market and building a successful pimavanserinfranchise."

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on innovative treatmentsthat address unmet medical needs in neurological and related centralnervous system disorders. ACADIA has a pipeline of product candidatesled by pimavanserin, which is in Phase III development as a potentialfirst-in-class treatment for Parkinson's disease psychosis. ACADIA alsohas clinical-stage programs for chronic pain and glaucoma incollaboration with Allergan, Inc. and two advanced preclinical programsdirected at Parkinson’s disease and other neurological disorders. Allproduct candidates are small molecules that emanate from discoveriesmade at ACADIA. ACADIA maintains a website at www.acadia-pharm.comto which ACADIA regularly posts copies of its press releases as well asadditional information and through which interested parties cansubscribe to receive email alerts.

Forward-Looking Statements

Statements in this press release that are not strictly historical innature are forward-looking statements. These statements include but arenot limited to statements related to the progress and timing of ACADIA’sdrug discovery and development programs, either alone or with a partner,including clinical trials, the benefits to be derived from ACADIA’sproduct candidates, including pimavanserin, the timing of an NDAsubmission for pimavanserin, the timing of pre-commercial and commercialactivities, the expected contributions of Mr. Moore to ACADIA’sbusiness, the success of any launch, the life cycle management orcommercial potential of pimavanserin, or the ability to create apimavanserin franchise. These statements are only predictions based oncurrent information and expectations and involve a number of risks anduncertainties. Actual events or results may differ materially from thoseprojected in any of such statements due to various factors, includingthe risks and uncertainties inherent in drug discovery, development andcommercialization, and collaborations with others, building andmaintaining a commercial organization and the fact that past results ofclinical trials may not be indicative of future trial results. For adiscussion of these and other factors, please refer to ACADIA’s annualreport on Form 10-K for the year ended December 31, 2012 as well asACADIA’s subsequent filings with the Securities and Exchange Commission.You are cautioned not to place undue reliance on these forward-lookingstatements, which speak only as of the date hereof. This caution is madeunder the safe harbor provisions of the Private Securities LitigationReform Act of 1995. All forward-looking statements are qualified intheir entirety by this cautionary statement and ACADIA undertakes noobligation to revise or update this press release to reflect events orcircumstances after the date hereof, except as required by law.

Source: ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc.
Uli Hacksell, Ph.D., ChiefExecutive Officer
Lisa Barthelemy, Director of InvestorRelations
(858) 558-2871